摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[3-{4-(2-Pyrimidinyl)-1-piperazinyl}propyl]-cyclohexane-1,2-dicarboximide | 770666-31-4

中文名称
——
中文别名
——
英文名称
N-[3-{4-(2-Pyrimidinyl)-1-piperazinyl}propyl]-cyclohexane-1,2-dicarboximide
英文别名
2-[3-(4-Pyrimidin-2-ylpiperazin-1-yl)propyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione
N-[3-{4-(2-Pyrimidinyl)-1-piperazinyl}propyl]-cyclohexane-1,2-dicarboximide化学式
CAS
770666-31-4
化学式
C19H27N5O2
mdl
——
分子量
357.456
InChiKey
AGKAUHMPMKTEGZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    69.6
  • 氢给体数:
    0
  • 氢受体数:
    6

文献信息

  • Succinimide derivatives and their production
    申请人:SUMITOMO CHEMICAL COMPANY, LIMITED
    公开号:EP0109562A1
    公开(公告)日:1984-05-30
    A succinimide derivative of the formula: wherein A is straight or branched C2-C6 alkylene or alkenylene, B is straight or branched C3-C5 alkylene, D is straight or branched C2-C3 alkylene, E is straight or branched C2-C3 alkylene, R1 and R2 are each hydrogen or C1-C4 alkyl, or they may form a single bond and R3 is a phenyl group optionally substituted with C1-C4 alkyl, C1-C4 alkoxy, halogen and or trifluoromethyl, a 2-pyridyl group optionally substituted with halogen, a 2-pyrimidyl group optionally substituted with halogen, a group of the formula: (in which R4 is hydrogen or phenyl), a group of the formula: CO-R5 (in which R5 is adamantyl or furyl) or hydroxy(C2-C4)alkyl, and an acid addition salt thereof, which are useful as anti-anxiety drugs and/or anti-allergic drugs.
    一种琥珀酰亚胺生物,其式如下 其中 A 为直链或支链 C2-C6 亚烷基或烯基,B 为直链或支链 C3-C5 亚烷基,D 为直链或支链 C2-C3 亚烷基,E 为直链或支链 C2-C3 亚烷基,R1 和 R2 各为氢或 C1-C4 烷基,或它们可形成单键,R3 为任选被 C1-C4 烷基、C1-C4 烷氧基、卤素和或三甲基取代的苯基,任选被卤素取代的 2-吡啶基,任选被卤素取代的 2-嘧啶基,式中的一个基团: (其中 R4 为氢或苯基)、式中的一个基团: CO-R5(其中 R5 为金刚烷基或呋喃基)或羟基(C2-C4)烷基,以及它们的酸加成盐,可用作抗焦虑药和/或抗过敏药。
  • 5 HT RECEPTOR MEDIATED NEUROGENESIS
    申请人:Barlow Carrolee
    公开号:US20100009983A1
    公开(公告)日:2010-01-14
    The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.
  • US4598078A
    申请人:——
    公开号:US4598078A
    公开(公告)日:1986-07-01
查看更多